Clarifying Conflict of Interest

American Journal of Bioethics

Volumn 11, Issue 1, 2011, Pages 23-28

  Brody, Howard ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

biomedical research; conflict of interest; pharmaceutical industry; professional ethics; regulatory issues

Indexed keywords

ARTICLE; BIOTECHNOLOGY; CLINICAL TRIAL (TOPIC); CONFLICT OF INTEREST; DRUG INDUSTRY; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; GENERAL PRACTITIONER; HUMAN; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PATIENT ADVOCACY; PATIENT EDUCATION; PHYSICIAN; PUBLIC OPINION; PUBLIC RELATIONS; TEACHING; TRUST; UNITED STATES;

BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS; INTERPROFESSIONAL RELATIONS; PATIENT ADVOCACY; PATIENT EDUCATION AS TOPIC; PHYSICIANS; PHYSICIANS, FAMILY; PRIVATE SECTOR; PUBLIC OPINION; RESEARCH SUPPORT AS TOPIC; SOCIETIES, MEDICAL; TEACHING MATERIALS; TRUST; UNITED STATES;

EID: 79952478751     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2010.534530     Document Type: Article

References (40)

1. Abramson, J. 2004. Overdo$ed America: The broken promise of American medicine, New York: HarperCollins.
2. And the Winner Is-Pharmapologist. 2009. Hooked: Ethics, medicine and pharma, April 19. Available at: http://brodyhooked.blogspot.com/2009/04/and-winner-is-pharmapologist.html (accessed April 24, 2010)
3. Angell, M. 2004. The truth about the drug companies: How they deceive us and what to do about it, New York: Random House.
4. AAMC Task Force. 2008. Industry funding of medical education, Washington, DC: Association of American Medical Colleges. Available at: https://services.aamc.org/publications/showfile.cfm?file=version114.pdf&prd_id=232&prv_id=281&pdf_id=114 (accessed April 24, 2010)
5. Avorn, J. 2004. Powerful medicines: The benefits, risks, and costs of prescription drugs, New York: Knopf.
6. Brennan, T. A., Rothman, D. J.Blank, L. 2006. Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. Journal of the American Medical Association, 295: 429-433.
7. Brody, H. 2007. Hooked: Ethics, the medical profession, and the pharmaceutical industry, Lanham, MD: Rowman and Littlefield.
8. Brody, H. 2010. Professional medical organizations and commercial conflicts of interest: Ethical issues. Annals of Family Medicine, 8: 354-358.
9. Brody, H. In press. Conflict of interest between medicine and the pharmaceutical industry: Definitions and narratives. Journal of Medicine and Philosophy,
10. Campbell, E. G., Gruen, R. L. M.Mountford, J. 2007. A national survey of physician-industry relationships. New England Journal of Medicine, 356: 1742-1750.
11. Eichacker, P. Q., Natanson, C.Danner, R. L. 2007. Separating practice guidelines from pharmaceutical marketing [letter to editor and reply]. Critical Care Medicine, 35: 2877-2878.
12. Epstein, R. A. 2007. Conflicts of interest in health care: Who guards the guardians?. Perspectives in Biology and Medicine, 50: 72-88.
13. Erde, E. L. 1996. "Conflicts of interest in medicine: A philosophical and ethical morphology". In Conflicts of interest in clinical practice and research, Edited by: Speece, R. G., Shimm, D. S. and Buchanan, A. E. 12-41. New York: Oxford University Press.
14. Figueiras, A., Caamaño, F. and Gestal-Otero, J. J. 2000. Influence of physician's education, drug information and medical-care settings on the quality of drugs prescribed. European Journal of Clinical Pharmacology, 56: 747-753.
15. Greenland, S. 2009. Accounting for uncertainty about investigator bias: Disclosure is informative. Journal of Epidemiology and Community Health, 63: 593-598.
16. Guyatt, G. and Rennie, D. 2002. User's guide to the medical literature: A manual for evidence-based clinical practice, Chicago: AMA Press.
17. Heim, L. 2010. Identifying and addressing potential conflicts of interest: A professional medical organization's code of ethics. Annals of Family Medicine, 8: 359-361.
18. Heim, L. and Henley, D. 2009. Personal communication to author, November 30.
19. Hirsch, L. J. 2009. Conflicts of interest, authorship, and disclosures in industry-related scientific publications: The tort bar and editorial oversight of medical journals. Mayo Clinic Proceedings, 84: 811-821.
20. Kassirer, J. P. 2005. On the take: How medicine's complicity with big business can endanger your health, New York: Oxford University Press.
21. Lenzer, J. 2004. FDA bars own expert from evaluating risks of painkillers. British Medical Journal, 329: 1203
22. Lexchin, J., Bero, L. A., Djulbegovic, B. and Clark, O. 2003. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical Journal, 326: 1167-1170.
23. Lo, B. and Field, M. J., eds. 2009. Conflict of interest in medical research, education and practice, Washington, DC: National Academies Press.
24. Lurie, P. 2007. Presentation before the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice. Public Citizen, November 5. Available at: http://www.citizen.org/publications/publicationredirect.cfm?ID=7553 (accessed April 24, 2010)
25. May, C. F. 1961. Selling drugs by "educating" physicians. Journal of Medical Education, 36: 1-23.
26. Mertens, M. 2009. Family doctors sign educational deal with Coca-Cola. Shots-NPR Health Blog, October 15. Available at: http://www.npr.org/blogs/health/2009/10/family_doctors_sign_educationa.html (accessed April 24, 2010)
27. Murray, J. L. 2010. Coke and the AAFP-The real thing or a dangerous liaison?. Family Medicine, 42: 57-58.
28. Schafer, A. 2004. Biomedical conflicts of interest: the sequestration thesis-Learning from the cases of Nancy Olivieri and David Healy. Journal of Medical Ethics, 30: 8-24.
29. Shaw, G. B. 1980. The doctor's dilemma., New York: Penguin.
30. Shaywitz, D. A. and Stossel, T. P. 2009. It's time to fight the 'pharmascolds.'. Wall Street Journal, April 8. Available at: http://online.wsj.com/article/SB123914780537299005.html (accessed April 24, 2010)
31. Simmons, G. H. 1907. The commercial domination of therapeutics and the movement for reform. Journal of the American Medical Association, 48: 1645-1653.
32. Silverman, M. and Lee, P. R. 1974. Pills, profits and politics., Berkeley: University of California Press.
33. Stell, L. K. 2010. Avoiding over-deterrence in managing physicians' relationships with industry. American Journal of Bioethics, 10(1): 27-29.
34. Stossel, T. P. 2005. Regulating academic-industrial research relationships-Solving problems or stifling progress?. New England Journal of Medicine, 353: 1060-1064.
35. Stossel, T. P. 2007a. Divergent views on managing clinical conflicts of interest. Mayo Clinic Proceedings, 82: 1013-1014.
36. Stossel, T. P. 2007b. Regulation of financial conflicts of interest in medical practice and medical research: A damaging solution in search of a problem. Perspectives in Biology and Medicine, 50: 54-71.
37. Susman, J. 2009. Do things really go better with Coke?. Journal of Family Practice, 58: 630
38. Wadman, M. 2009. Money in biomedicine: The senator's sleuth. Nature, 461: 330-334.
39. Wazana, A. 2000. Physicians and the pharmaceutical industry: Is a gift ever just a gift?. Journal of the American Medical Association, 283: 373-380.
40. Weber, M. A. 2009. Academic physicians confront a hostile world: The creation of ACRE. Journal of Clinical Hypertension, 11: 533-536.